Publications

9. van den Akker, F. & Hol, W.G.J. (1999) Difference density quality (DDQ): A method to assess the global and local correctness of macromolecular crystal structures. Acta Cryst. D55, 206-218.[Medline][PDF]

12. Chatterjee-Kishore, M., van den Akker, F., Stark, G.R. Association of STATs with relatives and friends (2000). Trends in Cell Biology 10, 106-111.[Medline]

13. Chatterjee-Kishore, M., van den Akker, F., Stark, G.R. Adenovirus E1A down-regulates LMP2 transcription by interfering with the binding of STAT1 to IRF1 (2000). J. Biol. Chem. 275, 20406-20411. [Medline]

14. van den Akker, F., Zhang, X., Masaru, M., Huo, X., Misono, K.S., Yee, V.C. (2000) Crystal structure of the dimerized hormone binding domain of a guanylyl cyclase coupled receptor. Nature, 406, 101-104. [Medline]

15. van den Akker, F. Detailed analysis of the atrial natriuretic factor receptor hormone binding domain crystal structure (2001). Can. J. Physiol. Pharmacol., 79, 692-704. [Medline]

16. van den Akker, F. Structural insights into the ligand binding domains of membrane bound guanylyl cyclases and natriuretic peptide receptors (2001). J. Mol. Biol. 311, 92. [Medline]

17. Chen, X., Bhandari, R., Vinkemeier, U., van den Akker, F., Darnell, J.E. Jr. & Kuriyan, J. A reinterpretation of the dimerization interface of the N-terminal domains of STATs (2003). Protein Science.,12, 361-365. [Medline]

18. Ramamurthy, V., Roberts, M., van den Akker, F., Niemi, G., Reh, T.A., Hurley, J.B. AIPL1, a protein implicated in Leber's congenital amaurosis, interacts with and aids in processing of farnesylated proteins (2003). PNAS 100, 12630-12635. [Medline]

19. Padayatti, P.S., Helfand , M.S., Totir, M.A., Carey, M.P., Hujer, H.M., Carey,P.R., Bonomo, R.A., & van den Akker, F. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 Å crystal structure (2004). Biochemistry, 43, 843-848. [Medline]

20. Hall, P.R., Zheng, R., Pusztai-Carey, M., van den Akker, F., Carey, P.R., & Yee, V.C. Expression and crystallization of several forms of the Propionibacterium shermanii transcarboxylase 5S subunit (2004). Acta Cryst. D60, 521-523. [Medline]

21. Bartels, C.F., Bukulmez, H., Padayatti, P., Rhee, D.K., Van Ravenswaaij-Arts, C., Pauli, R.M., Mundlos, S., Chitayat, D., Shih, L.Y., Al-Gazali, L.I., Kant, S., Cole, T., Morton, J., Cormier-Daire, V., Faivre, L., Lees, M., Kirk, J., Mortier, G.R., Leroy, J., Zabel, B., Kim, C.A., Crow, Y., Braverman, N.E., van den Akker, F., Warman, M.L. Mutations in the Transmembrane Natriuretic Peptide Receptor NPR-B Impair Skeletal Growth and Cause Acromesomelic Dysplasia, Type Maroteaux (2004). Am. J. Hum. Genet. 75, 27-34. [Medline]

22. Padayatti, P.S., Helfand, M.S., Totir, M.A., Carey, M.P., Carey, P.R., Bonomo, R.A., van den Akker, F. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 beta-lactamase (2005). J. Biol. Chem., 280, 34900-34907. [Medline]

23. Padayatti, P.S., Sheri, A., Totir, M.A., Helfand, M.S., Carey, M.P., Anderson, V.A., Carey, P.R., Bethel, C.R., Bonomo, R.A., Buynak, J.D., van den Akker, F. Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28A crystal structure of wt SHV-1 complex with a penam sulfone (2006). J. Am. Chem. Soc., 128, 1325-13242. [Medline]

24. Totir, M.A., Padayatti, P.S., Helfand, M.S., Carey, M.P., Bonomo, R.A., Carey, P.R., van den Akker, F. The effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates (2006). Biochemistry, 45, 11895-11904. [Medline]

25. Ma., X., Sayed, N., Beuve, A., van den Akker, F. NO and CO differentially activate soluble guanylyl cyclase via a heme pivot-bend mechanism (2007). EMBO J., 26, 578-588. [Medline]

26. Ke, W., Bethel, C.R., Thomson, J.M., Bonomo, R.A., van den Akker, F. Crystal structure of KPC-2: Insights into carbapenemase activity in class A beta-lactamases (2007). Biochemistry E-pub 19-Apr-07, [Medline]

27. Helfand, M.S., Taracila, M.A., Totir, M.A., Padayatti, P.S., Bonomo, R.A., Buynak, J.D., van den Akker, F., Carey, P.R. Raman crystallographic studies of the inhibition intermediates formed in the Ser130Gly SHV, a Class A b-lactamase that confers resistance to clinical inhibitors (2007). Biochemistry 46, 8689-8699. [Medline]

28. Sayed, N., Baskaran, P., Ma, X., van den Akker, F., Beuve, A. Desensitization of soluble guanylyl cyclase, the NO-receptor, by S-nitrosylation (2007). PNAS 104, 12312-12317. [Medline]

29. Ma, X., Sayed, N., Beuve, A., & van den Akker, F. PAS-like dimerization of soluble guanylyl cyclase revealed by signal transduction histidine kinase domain structure (2007). J. Biol. Chem. 283, 1167-1178. [Medline]

30. Pattanaik, P., Bethel, C.R., Hujer, A.M., Hujer, K.M., Distler, A.M., Taracila, M., Anderson, V.E., Fritsche, T.R., Jones, R.N., Ram Reddy Pagadala, S., van den Akker, F.*, Buynak, J.D.*,Bonomo, R.A.* Strategic design of an effective beta -lactamase Inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone (2009). J. Biol. Chem. 284, 945-953. *Co-corresponding authors [Medline]

31. Pattanaik, P., Fromondi, L., Ng, K.P., He., J., van den Akker, F. Expression, purification, and characterization of the intracellular domain of the ANP receptor (2009). Biochimie, 91, 888-893. [Medline]

32. Ma., X., Beuve, A., van den Akker, F. Crystal structure of the signaling helix coiled-coil doimain of the beta1 subunit of the soluble guanylyl cyclase (2010). BMC Struct. Biol. 10:2. [Medline]

33. Martin, F., Baskaran, P., Ma, X., Dunten, P.W., Schaefer, M., Stasch, J.P., Beuve, A. & van den Akker, F. Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase (2010) J. Biol. Chem. 285, 22651-7. [Medline]

34. Bou, G., Santillana, E., Sheri, A., Beceiro, A., Sampson, J.M., Kalp, M., Bethel, C.R., Distler, A.M., Drawz, S.M., Pagadala, S.R.R., van den Akker, F., Bonomo, R.A., Romero, A., Buynak, J.D. (2010) Design, synthesis, and crystal structures of 6-alkylidene-2’-substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase (2010). J.A.C.S. 132, 13320-13331. [Medline]

35. Tsai, A.L.*, Berka, V., Martin, F., Ma, X., van den Akker, F.*, Fabian, M., Olson, J.S. Is Nostoc H-NOX a NO sensor or redox switch? (2010) Biochemistry 49, 6587-6599 *co-corresponding authors [Medline]

36. Novel insights into the mode of inhibition of class A SHV-1 ?-lactamase revealed by boronic acid transition state inhibitors (2011) Ke, W., Sampson, J.M., Ori, C., Prati, F., Drawz, S.M., Bethel, C.R.,Bonomo, R.A, van den Akker, F. Antimicrobial Agents and Chemotherapy. Epub 2010 Nov 1, 55, 174-183 [Medline]

37. Ligand dependent disorder of ? loop observed in extended-spectrum phenotype SHV-1 ?-lactamase (2011) Sampson, J.M., Ke, W., Bethel, C.R., Pagadala, S.R.R., Nottingham, M.D., Bonomo, R.A., Buynak, J.D., van den Akker, F. Accepted in Antimicrobial Agents and Chemotherapy. [Medline]

38. Modifications of the C6-substituent of penicillin sulfones with the goal of improving inhibitor recognition and efficacy (2011). Nottingham, M., Bethel, C.R., Pagadala, S.R., Harry, E., Pinto, A., Lemons, Z.A., Drawz, S.M., van den Akker, F., Carey, P.R., Bonomo, R.A., Buynak, J.D. Bioorg. & Med. Chem. Lett. 21, 387-393. [Medline]

39. Aspartate 102 in the heme domain of soluble guanylyl cyclase has a key role in NO activation (2011). Baskaran, P., Heckler, E., van den Akker, F.*, Beuve, A.* Biochemistry 50, 4291-4297. [Medline]

40. Identification of key residues in the heme domain of soluble guanylyl cyclase that mediate basal and stimulated catalytic activity (2011). Baskaran, P., Heckler, E., van den Akker, F.*, Beuve, A.* Plos One, 6(11), e26976. [Medline]

41. Crystal structures of KPC-2 ?-lactamase in complex with 3-NPBA and PSR-3-226 (2012) Ke, W, Bethel, C.R., Papp-Wallace, K.M., Pagadala, S.R., Nottingham, M., Fernandez, D., Buynak, J.D., Bonomo, R.A., van den Akker, F. Antimicrob Agents Chemother. 56, 2713-2718. [Medline]

42. The importance of the trans-enamine intermediate as a ?-lactamase inhibition strategy probed in inhibitor-resistant SHV ?-lactamase variants (2012). Ke, K, Rodkey, R.A., Sampson, J.M.a, Skalweit, M.J., Sheri, A., Pagadala. S.R.R., Nottingham, M.D., Buynak, J.D., Bonomo, R.A., van den Akker, F. ChemMedChem, 7, 1002-1008. [Medline]

43. Structure of an Engineered ?-Lactamase Maltose Binding Protein Fusion Protein: Insights into Heterotropic Allosteric Regulation (2012). Ke, W., Laurent, A.H., Armstrong, M.D., Chen, Y., Smith, W.E., Liang, J., Wright, C.M., Ostermeier, M., and van den Akker, F. Plos One, 7(6), e39168.. [Medline]